Lobewell

Six-month weight-loss programme for fatty liver patients, run for liver clinics

TL;DR Lobewell runs a six-month, dietitian-led weight-loss programme for people who've been told they have fatty liver. Gastroenterology and liver clinics refer patients, and the patient pays. The promise is one you can measure - a repeat liver scan at the end shows whether the weight came off and whether it helped.

The problem

Fatty liver is far more common in India than most people think. A meta-analysis put pooled prevalence at 38.6% of adults and 35.4% of children[1]. Among adults with type 2 diabetes, a 2026 review found 56.9%, rising to 64.3% where elastography scans were used[2].

The treatment is mostly weight loss, and that's exactly where patients fall short. In a year-long study of 293 patients, those who lost 10% or more of their weight saw steatohepatitis resolve in 90% of cases, yet only 30% of the group managed even 5%[3]. A clinic visit every three months with a printed diet sheet is not going to close that gap.

The idea

What it does, in regulatory terms: lifestyle coaching under the referring doctor. It does not diagnose, stage fibrosis, prescribe or adjust medicines. The treating doctor orders and reads every scan and blood test.

A clinic refers a patient with a scan report. A dietitian builds a meal plan around the patient's home food and schedule, then checks in every week for six months by call and chat, logging weight, waist and food photos. A physical trainer adds a simple activity plan. The clinic gets a one-page summary every month and repeats the liver scan at six months.

I reframed the seed. It aimed AI coaching at metabolic dysfunction in general, which is a space where Indian diabetes and weight programmes already fight it out. Fatty liver gives you a narrower buyer in the liver clinic, and an outcome both patient and doctor can see on a scan.

Who pays

The patient pays, on a doctor's referral. I couldn't find a public price for fatty liver coaching in India, and the big digital diabetes programmes don't list prices for their diabetes or weight programmes either[4], so you'll set the fee in pilots. Clinics get a follow-up service they don't have to staff. Employers and insurers come later, once you have outcome data.

Why now

Fatty liver has moved up doctors' agendas. In March 2024 the US FDA approved resmetirom, the first drug for liver scarring from fatty liver, but only alongside diet and exercise[5]. Drug research keeps reporting modest liver-fat gains on top of lifestyle change[6]. So doctors still need a way to make lifestyle change actually happen.

Market signal

There's no public figure for India's fatty liver programme market. The narrow signal is the patient pool - 38.6% of adults[1] and more than half of adults with type 2 diabetes[2]. Adjacent: Indian digital diabetes and weight programmes already sell six to twelve month plans[4], which shows patients will pay for coaching over months.

Who's already doing this

Digital diabetes and weight-loss programmes in India show no fatty liver programme on their homepages[4]. Hospitals run dietitian clinics, but follow-up between visits is thin. I didn't find an Indian service built around liver-clinic referrals with a repeat scan as the endpoint. That combination is the gap, and it's a real one.

How hard is it?

Difficulty Moderate (38/100)
Starting capital ₹55–95 L
Time to launch 4–6 months

The app can be basic. The hard part is keeping patients going for six months and winning over liver specialists, who will judge you on scan results and nothing else. You also need dietitians who can plan for regional Indian diets (poha in Pune is not appam in Kochi).

Licences and approvals

No special licence for lifestyle coaching, as long as it stays coaching.

  • Telemedicine Practice Guidelines 2020 from launch. Dietitians coach, only registered doctors prescribe, and any doctor consult follows the guidelines[7].
  • Medical-device rules under CDSCO's software classes if a feature grades liver disease or guides treatment. Keep the product to coaching and logging[8].
  • DPDP Act consent from the patient before you share progress with the referring clinic[9].
  • Claims discipline before any marketing. Don't promise reversal, since results come only with enough weight loss[3].
  • Company registration with the MCA and GST once over the threshold.

Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.

How AI can power this business

  • Food photo logging. Estimate portions from meal photos so the dietitian spends check-ins on advice, not data entry.
  • Regional meal plans. Draft swaps within the patient's own cuisine, which the dietitian edits before sending.
  • Drop-off alerts. Spot patients whose logging or weight trend slips, so the dietitian calls them that week before they drift off.
  • Clinic summaries. Draft the monthly one-page update for the referring doctor from logged weight and waist data.

AI shouldn't read scans, stage fibrosis or touch medicines. Those stay with the treating doctor, as the page says.

Want to work out the AI layer for Lobewell? Talk to Yash →

Biggest risks

  • Drop-off. If most patients quit by month three then scans will show little change and clinics will stop referring.
  • Doctor trust. Specialists may see an outside programme as a threat to their patients or reputation.
  • Drugs as a shortcut. Weight-loss drugs may make patients and doctors less keen on coaching.

Our take

This is a solid idea with a clear proof point, which I like. It suits a founder with clinical nutrition or chronic-care operations experience who can sell to doctors. If you want a general wellness app then look elsewhere. First prove that 40% of referred patients lose at least 5% of their weight in six months.

Questions founders ask

Plan for roughly ₹55–95 L, mostly for dietitians, trainers and the months spent winning referrals from liver clinics.

Is a fatty liver coaching business profitable in India?

That depends on keeping patients for six months and getting steady clinic referrals. Prove 40% of patients lose at least 5% of their weight before you scale.

Can I start a fatty liver programme in another country?

Yes, fatty liver is common worldwide. Check local rules on dietitian practice, telehealth and health data first.

Download the kit

The free Lobewell validation kit has the line-by-line capital breakdown, the effort scoring, the telemedicine and data-protection checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for patients and clinics, and 5 assumptions to test. Download the kit →

Talk to Yash

Thinking about building Lobewell or something close to it? The make-or-break work is keeping referred patients losing weight long enough for the repeat scan to show it, and I'm glad to work through that with you. If you need a hand, you know where to find me. Talk to Yash →

Sources

  1. Shalimar et al., "Prevalence of non-alcoholic fatty liver disease in India: systematic review and meta-analysis", Journal of Clinical and Experimental Hepatology 12(3), 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9168741/
  2. Singhai et al., "Prevalence of MASLD in type 2 diabetes in India: systematic review and meta-analysis", Indian Journal of Medical Research, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13363007/
  3. Vilar-Gomez et al., "Weight loss through lifestyle modification reduces features of NASH", Gastroenterology 149(2), 2015. https://doi.org/10.1053/j.gastro.2015.04.005
  4. Fitterfly, official site, accessed 2026-10-21. https://www.fitterfly.com/
  5. US FDA, "FDA approves first treatment for patients with liver scarring due to fatty liver disease", 2024-03-14. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
  6. Joshi et al., "Dapagliflozin and pioglitazone in T2DM with or without MASLD: meta-analysis", Frontiers in Clinical Diabetes and Healthcare 7, 2026. https://doi.org/10.3389/fcdhc.2026.1733995
  7. MoHFW, "Telemedicine Practice Guidelines", 2020-03-25. https://esanjeevani.mohfw.gov.in/assets/guidelines/Telemedicine_Practice_Guidelines.pdf
  8. Morulaa, "CDSCO Software as Medical Device classification in India", 2026-09-16. https://morulaa.com/knowledge-hub/regulations/india/cdsco-medical-device-classification-software
  9. DPDPA.com, "DPDP Act 2023, Section 6: Consent", accessed 2026-10-21. https://www.dpdpa.com/dpdpa2023/chapter-2/section6.html

For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.

Reviews

No reviews yet